Pacific released a research report on April 9 stating that Enhua Pharmaceutical (002262.SZ) was given a purchase rating. The main reasons for the rating include: 1) the steady growth of the narcotics line and the rapid growth of the commercial sector; 2) expenses declined during the period, and the net interest rate remained stable; 3) large single anesthetic analgesia products are expected to be released, contributing to the increase in the introduction of drugs for rare diseases. (Mainichi Keizai Shimbun)
太平洋4月9日发布研报称，给予恩华药业（002262.SZ）买入评级。评级理由主要包括：1）麻醉线稳定增长，商业板块快速增长；2）期间费用有所下降，净利率维持稳定；3）麻醉镇痛大单品有望放量，引进罕见病用药贡献增量。（每日经济新闻）
Pacific released a research report on April 9 stating that Enhua Pharmaceutical (002262.SZ) was given a purchase rating. The main reasons for the rating include: 1) the steady growth of the narcotics line and the rapid growth of the commercial sector; 2)
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.